Prediabetes mellitus and its links to atherosclerosis

Current Diabetes Reports

Volumn 3, Issue 1, 2003, Pages 11-18

  Kramer, Daniel ^b   Raji, Annaswamy ^b   Plutzky, Jorge ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE;

ATHEROSCLEROSIS; CLINICAL PRACTICE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MECHANISM; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MORBIDITY; MORTALITY; OBESITY; PATHOPHYSIOLOGY; REVIEW; ARTERIOSCLEROSIS; CORONARY ARTERY DISEASE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS;

ARTERIOSCLEROSIS; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; HUMANS; METABOLIC SYNDROME X; PREDIABETIC STATE;

EID: 0037314387     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-003-0047-4     Document Type: Review

References (62)

1. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287:356-359.
2. Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
3. Haffner SM: Do interventions to reduce coronary heart disease reduce the incidence of type 2 diabetes? A possible role for inflammatory factors. Circulation 2001, 103:346-347.
4. Beckman JA, Creager MA, Libby P: Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002, 287:2570-2581.
5. Ginsberg HN: Insulin resistance and cardiovascular disease. J Clin Invest 2000, 106:453-458.
6. Thompson WG: Early recognition and treatment of glucose abnormalities to prevent type 2 diabetes mellitus and coronary heart disease. Mayo Clin Proc 2001, 76:1137-1143.
7. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) [no authors listed]. JAMA 2001,285:2486-2497.
8. Haffner SM, Mykkanen L, Festa A, et al.: Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 2000, 101:975-980.
9. Reaven G: Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 2002, 106:286-288.
10. Reaven GM: Pathophysiology of insulin resistance in human disease. Physiol Rev 1995, 75:473-486.
11. Haffner SM: Impaired glucose tolerance, insulin resistance and cardiovascular disease. Diabet Med 1997, 14(suppl 3):S12-S18.
12. Maison P, Byrne CD, Hales CN, et al.: Do different dimensions of the metabolic syndrome change together over time? Evidence supporting obesity as the central feature. Diabetes Care 2001, 24:1758-1763.
13. McGill HC Jr, McMahan CA, Herderick EE, et al.: Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation 2002, 105:2712-2718.
14. Shulman GI: Cellular mechanisms of insulin resistance. J Clin Invest 2000, 106:171-176.
15. Kahn BB, Flier JS: Obesity and insulin resistance. J Clin Invest 2000, 106:473-481.
16. Beck-Nielsen H, Groop LC: Metabolic and genetic characterization of prediabetic states. Sequence of events leading to non-insulin-dependent diabetes mellitus. J Clin Invest 1994, 94:1714-1721.
17. Tominaga M, Eguchi H, Manaka H, et al.: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999, 22:920-924.
18. Despres JP, Lamarche B, Mauriege P, et al.: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996, 334:952-957.
19. Ridker PM, Stampler MJ, Rifai N: Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001, 285:2481-2485.
20. Diercks GF, van Boven AJ, Hillege JL, et al.: The importance of microalbuminuria as a cardiovascular risk indicator: a review. Can J Cardiol 2002, 18:525-535.
21. Garg JP, Bakris GL: Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med 2002, 7:35-43.
22. Miyazaki H, Matsuoka H, Cooke JP, et al.: Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999, 99:1141-1146.
23. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM: Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002, 51:1131-1137.
24. Pradhan AD, Manson JE, Rifai N, et al.: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327-334.
25. Bjornholt JV, Erikssen G, Liestol K, et al.: Type 2 diabetes and maternal family history: an impact beyond slow glucose removal rate and fasting hyperglycemia in low-risk individuals? Results from 22.5 years of follow-up of healthy nondiabetic men. Diabetes Care 2000, 23:1255-1259.
26. Harris MI: Epidemiological correlates of NIDDM in Hispanics, whites, and blacks in the U.S. population. Diabetes Care 1991, 14:639-648.
27. Harris SB, Zinman B: Primary prevention of type 2 diabetes in high-risk populations. Diabetes Care 2000, 23:879-881.
28. McClain MR, Srinivasan SR, Chen W, et al.: Risk of type 2 diabetes mellitus in young adults from a biracial community: the Bogalusa Heart Study. Prev Med 2000, 31:1-7.
29. Kim C, Newton KM, Knopp RH: Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care 2002, 25:1862-1868.
30. Norman RJ, Masters L, Milner CR, et al.: Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod 2001, 16:1995-1998.
31. Cavaghan MK, Ehrmann DA, Polonsky KS: Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest 2000, 106:329-333.
32. Bergenstal RM, Kendall DM, Franz MJ, Rubenstein A: Management of type 2 diabetes: a systemic approach to meeting the standards of self-management education, medical nutrition therapy, and exercise. In Endocrinology, edn 4. Edited by Degroot LJ, Jameson JL. St. Louis, MO: W.B. Saunders; 2001:820-822.
33. Wei M, Gaskill SP, Haffner SM, Stern MP: Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 1998, 21:1167-1172.
34. Hu FB, Stampfer MJ, Haffner SM, et al.: Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002, 25:1129-1134.
35. Strong JP, Malcom GT, McMahan CA, et al.: Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA 1999, 281:727-735.
36. Toussaint JF, LaMuraglia GM, Southern JF, et al.: Magnetic resonance images lipid, fibrous, calcified, hemorrhagic, and thrombotic components of human atherosclerosis in vivo. Circulation 1996, 94:932-938.
37. Yuan C, Beach KW, Smith LH Jr, Hatsukami TS: Measurement of atherosclerotic carotid plaque size in vivo using high resolution magnetic resonance imaging. Circulation 1998, 98:2666-2671.
38. Hikita N, Tsuchihashi K, Nakata T, et al.: Involvement of glucose metabolism abnormalities and insulin resistance in atherosclerotic coronary artery disease: semiquantitative coronary angiography study [in Japanese]. J Cardiol 1998, 32:291-300.
39. Shinozaki K, Suzuki M, Ikebuchi M, et al.: Demonstration of insulin resistance in coronary artery disease documented with angiography. Diabetes Care 1996, 19:1-7.
40. Weidinger F, Frick M, Alber HF, et al.: Association of wall thickness of the brachial artery measured with high-resolution ultrasound with risk factors and coronary artery disease. Am J Cardiol 2002, 89:1025-1029.
41. Teragawa, H, Kato M, Kurokawa J, et al.: Usefulness of flow-mediated dilation of the brachial artery and/or the intima-media thickness of the carotid artery in predicting coronary narrowing in patients suspected of having coronary artery disease. Am J Cardiol 2001, 88:1147-1151.
42. Urbina EM, Brinton TJ, Elkasabany A, Berenson GS: Brachial artery distensibility and relation to cardiovascular risk factors in healthy young adults (The Bogalusa Heart Study). Am J Cardiol 2002, 89:946-951.
43. Haffner SM, Gonzales C, Valdez RA, et al.: Is microalbuminuria part of the prediabetic state? The Mexico City Diabetes Study. Diabetologia 1993, 36:1002-1006.
44. Gerstein HC, Mann JF, Pogue J, et al.: Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators. Diabetes Care 2000, 23(suppl 2):B35-B39.
45. Turner RC, Millns H, Neil HA, et al.: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998, 316:823-828.
46. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial [no authors listed]. Lancet 2002, 360:7-22.
47. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143.
48. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999, 340:115-126.
49. Knowler WC, Barrett-Connor E, Fowler SE, et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
50. Chiasson JL, Josse RG, Gomis R, et al.: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002, 359:2072-2077.
51. Wing RR, Venditti E, Jakicic JM, et al.: Lifestyle intervention in overweight individuals with a family history of diabetes. Diabetes Care 1998, 21:350-359.
52. Tuomilehto J, Lindstrom J, Eriksson JG, et al.: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350.
53. Chakravarthy MV, Joyner MJ, Booth FW: An obligation for primary care physicians to prescribe physical activity to sedentary patients to reduce the risk of chronic health conditions. Mayo Clin Proc 2002, 77:165-173.
54. Ludwig DSZ: The glycemic index: physiological mechanisms relating to obesity, diabetes, and cardiovascular disease. JAMA 2002, 287:2414-2423.
55. Westman EC, Yancy WS, Edman JS, et al.: Effect of 6-month adherence to a very low carbohydrate diet program. Am J Med 2002, 113:30-36.
56. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group [no authors listed]. Diabetes 1995, 44:1249-1258.
57. Buchanan TA, Xiang AH, Peters RK, et al.: Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002, 51:2796-2803.
58. Azen SP, Peters RK, Berkowitz K, et al.: TRIPOD (Troglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin Trials 1998, 19:217-231.
59. Kreisberg RA, Oberman A: Clinical review 141: lipids and atherosclerosis: lessons learned from randomized controlled trials of lipid lowering and other relevant studies. J Clin Endocrinol Metab 2002, 87:423-437.
60. Albert MA, Danielson E, Rifai N, Ricker PM: Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001, 286:64-70.
61. Ridker PM, Rifai N, Pfeffer MA, et al.: Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999, 100:230-235.
62. Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145-153.